Conformis, Inc. to Participate in the Canaccord Genuity 42nd Annual Growth Conference
BILLERICA, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today that Mark Augusti, Chief Executive Officer, and Bob Howe, Chief Financial Officer, will participate in the Canaccord Genuity 42nd Annual Growth Conference.
The conference will take place August 8-11, 2022. The conference will be held at the InterContinental Boston Hotel and bring together institutional investors from across the globe with some of the best and most promising growth companies in Technology, Healthcare & Life Sciences, Sustainability, Industrials, and Consumer & Retail.
Conformis management will present on Thursday, August 11 from 3:00 p.m. ET to 4:00 p.m. ET.
Conformis management will also be available for one-on-one meetings throughout the conference. For more information about the conference or to schedule a one-on-one meeting with management, please contact your Canaccord Genuity representative or contact Conformis Investor Relations at email@example.com and (781) 374-5598.
A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the Conformis website at ir.conformis.com. A replay of the webcast will be archived on Conformis' website for 90 days following the presentation.
About Conformis, Inc.
Founded in 2004, Conformis is a medical technology company focused on advancing orthopedic patient care and creating a world without joint pain. Its product portfolio is designed to maximize surgeon and patient choice by offering fully personalized solutions through its Image-to-Implant® Platinum Services℠ Program as well as data-informed, standardized solutions that combine many benefits of personalization with the convenience and flexibility of an off-the-shelf system. Conformis’ sterile, just-in-time, Surgery-in-a-Box™ delivery system is available with all of its implants and personalized, single-use instruments. Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints. For more information, visit www.conformis.com. To receive future press releases via e-mail alerts, sign up at ir.conformis.com.